Research paper

1

2

22

28

- 3 Gender differences in the determinants of willingness to get the
- 4 COVID-19 vaccine among the working-age population in Japan
- 5 Tomohiro Ishimaru^a*, Makoto Okawara^a, Hajime Ando^b, Ayako Hino^c,
- 6 Tomohisa Nagata^d, Seiichiro Tateishi^e, Mayumi Tsuji^f, Shinya Matsuda^g,
- 7 and Yoshihisa Fujino^a for the CORoNaWork Project
- 8 ^aDepartment of Environmental Epidemiology, Institute of Industrial Ecological
- 9 Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu,
- 10 Japan; ^bDepartment of Work Systems and Health, Institute of Industrial Ecological
- 11 Sciences, University of Occupational and Environmental Health, Japan, Kitakyushu,
- 12 Japan; ^cDepartment of Mental Health, Institute of Industrial Ecological Sciences,
- 13 University of Occupational and Environmental Health, Japan, Kitakyushu, Japan;
- 14 dDepartment of Occupational Health Practice and Management, Institute of Industrial
- 15 Ecological Sciences, University of Occupational and Environmental Health, Japan,
- 16 Kitakyushu, Japan; ^eDepartment of Occupational Medicine, School of Medicine,
- 17 University of Occupational and Environmental Health, Japan, Kitakyushu, Japan;
- 18 ^fDepartment of Environmental Health, School of Medicine, University of Occupational
- 19 and Environmental Health, Japan, Kitakyushu, Japan; ⁸Department of Preventive
- 20 Medicine and Community Health, School of Medicine, University of Occupational and
- 21 Environmental Health, Japan, Kitakyushu, Japan
- 23 *Corresponding author: Tomohiro Ishimaru, MD, MPH, PhD
- 24 Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences,
- 25 University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahata-nishi-ku,
- 26 Kitakyushu, Fukuoka 807-8555, Japan
- 27 Tel: +81-93-603-1611, Fax: +81-93-601-7324, email: ishimaru@med.uoeh-u.ac.jp

Gender differences in the determinants of willingness to get the

COVID-19 vaccine among the working-age population in Japan

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 48

49

50

51

52

53

54

55

56

57

58

Many factors are related to vaccination intentions. However, gender differences in the determinants of intention to get the coronavirus disease 2019 (COVID-19) vaccine have not been fully investigated. This study examined gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. We conducted a cross-sectional study of Japanese citizens aged 20-65 years using an online self-administered questionnaire in December 2020. Logistic regression analysis was performed. Among 27,036 participants (13,814 men and 13,222 women), the percentage who were willing to get the COVID-19 vaccine was lower among women than among men (33.0%) vs. 41.8%). Age and education level showed a gender gap regarding the association with willingness to get the COVID-19 vaccine: men who were older or had a higher level of education were more willing to get the vaccine, whereas women aged 30-49 years and those with a higher level of education showed a relatively low willingness to get the vaccine. For both men and women, marriage, higher annual household income, underlying disease, current smoking, vaccination for influenza during the current season, and fear of COVID-19 transmission were linked to a higher likelihood of being willing to get the COVID-19 vaccine. These findings give important insight into identifying target groups in need of intervention regarding COVID-19 vaccination, especially among women. Providing education about COVID-19 and influenza vaccination in the workplace may be an effective strategy to increase COVID-19 vaccine uptake.

Keywords: COVID-19; employees; infection; occupational health; SARS-CoV-2;

vaccine; working age

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

Introduction Vaccines are expected to be a key measure against the coronavirus disease 2019 (COVID-19) pandemic. Vaccine development usually takes decades, and, although a variety of COVID-19 vaccines are currently being developed at an unprecedented rate, evidence has not yet established their long-term safety.² In Japan, the COVID-19 vaccination program has been administered since February 2021, with eligibility proceeding in the following order: healthcare workers, older adults (aged 65 years or older), and people with underlying diseases and caregivers working at care facilities for older adults.³ Other people will become eligible for vaccination at a later date, following the populations listed above, which are the main sources of infection.⁴ To reach herd immunity, most citizens need to be vaccinated.⁵ Vaccination intentions are recognized as the most important issue in the rollout of vaccination programs. However, Japan is known for its lack of public trust in vaccines ⁷ because negative campaigns against the vaccination—highlighting scandals and severe adverse effects, for instance—have increased hesitation concerning some vaccinations over the past several decades.⁸⁻¹¹ For example, a national human papillomavirus vaccination program for girls was launched in 2013 but was discontinued after 3 months because of sensational case reports of adverse effects. 12 This event had a negative impact on vaccination intentions, especially among women.¹³ Various factors are related to COVID-19 vaccination intentions. Previous studies have reported that age, gender, race, education level, influenza vaccination status, and fear of COVID-19 transmission are associated with the willingness to get the COVID-19 vaccine. 14-18 In Japan, willingness to get the COVID-19 vaccine was previously

examined in a single study of 1,100 adults, with results showing that vaccine hesitancy was higher in Japan than in other countries, particularly among women. However, gender differences in the determinants of willingness to get the COVID-19 vaccine, such as demographic and health characteristics, influenza vaccination status, and fear of COVID-19 transmission, have not been fully investigated. Furthermore, more studies involving larger samples of the working-age population are needed. Therefore, the current study examined gender differences in the determinants of willingness to get the COVID-19 vaccine among the working-age population in Japan. This study will give important insight into identifying target groups in need of intervention regarding COVID-19 vaccination.

Materials and methods

Study design

We conducted a cross-sectional study about COVID-19 among the working-age population in Japan on December 22–26, 2020. The present article is part of a series of studies conducted under the CORoNaWork (Collaborative Online Research on the Novel-coronavirus and Work) Project. This study was conducted during the third wave of the COVID-19 pandemic in Japan, when the number of infected people and deaths peaked. Although COVID-19 vaccination began in December 2020 in the United Kingdom (UK) and the United States (US), Japan had not yet begun to administer COVID-19 vaccines during the survey period. Pfizer requested a fast-track approval of its COVID-19 vaccine from the government of Japan on December 18, 2020 and became the first company to receive this approval on February 14, 2021.

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

Criteria for eligibility for the present study were being aged 20–65 years and currently working. Healthcare workers and caregivers were not invited to participate. We recruited study participants from the panelists of Cross Marketing Inc. (Tokyo, Japan), an Internet research company. These panelists regularly respond to self-administered Internet surveys distributed by the company, receiving tokens that can be redeemed for products and services as compensation. For this survey, we used quota sampling by gender, residence (five districts), and occupation (office worker or other). Information on these characteristics was retrieved from the panelists' Cross Marketing Inc. registration information. Cross Marketing Inc. sent an invitation email to panelists who met the eligibility criteria, and those who were interested in the study proceeded to the survey via a hyperlink. The participants provided informed consent prior to beginning the online questionnaire. We set a quota of 1,650 participants for each of the 20 strata and ceased recruitment when the target number was reached. In total, 33,087 participants from all over Japan completed the questionnaire. After excluding invalid responses, a total of 27,036 participants remained. All participants received standard incentives through Cross Marketing Inc. (i.e., a few dollars' worth of tokens). The study was conducted according to the guidelines of the Declaration of Helsinki, and it was approved by the Ethics Committee of the University of Occupational and Environmental Health, Japan (Approval number: R2-079). Measures The survey questions included items on demographic and health characteristics, influenza vaccination status during the current season, fear of COVID-19 transmission, and willingness to get the COVID-19 vaccine. The demographic and health characteristics were gender, age, education, marital status, annual household income (1 USD was equal to 106.78 JPY, using 2020 conversion rates),²³ underlying disease, and smoking status. In line with a previous study,¹⁸ we developed the following item to assess willingness to get the COVID-19 vaccine: "If a COVID-19 vaccine becomes available, I will get it." The possible answers to this question were *yes* and *no*. Fear of COVID-19 transmission was assessed by asking "Do you fear COVID-19 transmission?", with *yes* and *no* as the possible responses.

Data analysis

We calculated frequencies and proportions for all variables. Descriptive statistics were also calculated by gender to reveal more detailed background factors. Logistic regression analysis was performed to calculate adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for all variables to evaluate associations with willingness to get the COVID-19 vaccine. Because we hypothesized that gender was an important determinant in the current study, the analysis was stratified by gender. We adjusted for age; no adjustments were made for the other covariates because the purpose of this study was to detect target populations for future intervention programs. All P-values were two-sided, and statistical significance was set at P < .05. We used Stata/SE 16.1 (StataCorp, College Station, TX, USA) for all analyses.

Results

Table 1 shows the characteristics of the study population. Data on a total of 27,036 participants (13,814 men and 13,222 women) were analyzed. We found that 43.0% of

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

the participants reported that they had received the influenza vaccine during the current season. Regarding fear of COVID-19 transmission, 74.0% indicated that they felt fear. Overall, 37.5% of the participants expressed that they would like to get a COVID-19 vaccine if it becomes available. Table 2 displays the characteristics of the study population by willingness to get the COVID-19 vaccine and gender. A total of 5,780 men (41.8%) and 4,367 women (33.0%) were willing to get the COVID-19 vaccine. Relatively high percentages of participants were willing to get the COVID-19 vaccine among those aged 60-65 years (men: 48.0%; women: 41.1%), those who had an underlying disease (men: 47.8%; women: 37.0%), those who felt fear of COVID-19 transmission (men: 49.5%; women: 37.0%), and those who had received the influenza vaccine during the current season (men: 59.2%; women: 43.7%). These percentages were higher in men than in women. Table 3 presents the factors associated with willingness to get the COVID-19 vaccine by gender. Men aged 50-59 years (aOR: 1.38; 95% CI: 1.02-1.86) and those aged 60-65 years (aOR: 1.76; 95% CI: 1.30-2.40) were more willing to get the COVID-19 vaccine than were men aged 20–29 years. Conversely, women aged 30–39 years (aOR: 0.86; 95% CI: 0.76–0.97) and those aged 40–49 years (aOR: 0.80; 95% CI: 0.71–0.91) were less willing to get the vaccine than were women aged 20–29 years. Regarding education level, compared with having a junior high or high school education, having a university or graduate school education was a facilitating factor for willingness to get the COVID-19 vaccine for men (aOR: 1.13; 95% CI: 1.04–1.22) but a barrier for women (aOR: 0.83; 95% CI: 0.75–0.91).

For both men and women, a significantly higher likelihood of willingness to get the COVID-19 vaccine was observed among those who were married (men—aOR: 1.37; 95% CI: 1.26-1.49; women—aOR: 1.30; 95% CI: 1.20-1.40), those with a higher annual household income (men—aOR: 1.91; 95% CI: 1.61-2.26; women—aOR: 1.32; 95% CI: 1.13–1.53), those with an underlying disease (men—aOR: 1.43; 95% CI: 1.34– 1.54; women—aOR: 1.29; 95% CI: 1.19–1.39), those who currently smoked (men— aOR: 1.20; 95% CI: 1.11–1.30; women—aOR: 1.36; 95% CI: 1.24–1.51), those who had been vaccinated against influenza during the current season (men—aOR: 3.28; 95% CI: 3.05–3.52; women—aOR: 2.53; 95% CI: 2.35–2.73), and those with a fear of COVID-19 transmission (men—aOR: 3.09; 95% CI: 2.85–3.35; women—aOR: 2.54; 95% CI: 2.29–2.81).

Discussion

This study provides evidence on gender differences in the determinants of willingness to get the COVID-19 vaccine. In the present study, the percentage of people who were willing to get the COVID-19 vaccine was lower among women than among men (33.0% vs. 41.8%). This trend was similar to the findings of previous studies in developed countries. ^{14, 19, 24, 25} Notably, we found a gender gap in the associations of age and education level with willingness to get the COVID-19 vaccine: men who were older or had a higher level of education were more willing to get the vaccine, whereas women aged 30–49 years and those with a higher level of education were less willing to get the vaccine. Other factors showed similar trends for men and women: for both men and women, a higher likelihood of being willing to get the COVID-19 vaccine was observed in married participants, those with a higher annual household income, those who had an underlying disease, those who currently smoked, those who had been vaccinated against

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

influenza during the current season, and those with a fear of COVID-19 transmission. These findings give important insight into identifying target groups for improving COVID-19 vaccination intentions, especially among women. The most notable finding of the present study was a gender gap in the associations of age and education with willingness to get the COVID-19 vaccine. As mentioned above, men who were older or had a higher level of education were more willing to get the vaccine, whereas women aged 30-49 years and those with a higher level of education were less willing to get the vaccine. For men, this finding is consistent with previous studies; older age and higher level of education are known facilitators for health protection, which should correlate with COVID-19 vaccination intentions. 24, 26, 27 Conversely, the current results for women vary from the findings presented in these studies. This difference may be explained by a higher level of concern about adverse effects of the vaccine among women aged 30-49 years and among those with a relatively high level of education in Japan during the current study period. We considered that recent reporting on adverse effects following receipt of the human papillomavirus vaccine in major Japanese newspapers may have had a negative impact on the vaccination intentions of these groups. ²⁸ These findings may imply the need for intervention in this population regarding COVID-19 vaccination. The current study found that influenza vaccination status and fear of COVID-19 transmission were strongly associated with willingness to get the COVID-19 vaccine among both men and women. These results are in line with previous studies. 16, 17, 29, 30 In the case of the 2009 influenza pandemic, perceived risk of infection translated into preventive behaviors, including vaccination.³¹ Similarly, the experience of receiving a

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

vaccine have been shown to increase an individual's confidence in the efficacy and safety of other vaccines.^{29, 30} Nevertheless, working-age people have fewer opportunities to receive the influenza vaccine compared with older adults because of the former group's busy work schedules.³² These findings suggest that providing education about COVID-19 and influenza vaccination in the workplace may be an effective strategy to increase COVID-19 vaccine uptake. In the current study, a higher likelihood of being willing to get the COVID-19 vaccine was observed among those who were married, those with a higher annual household income, those with an underlying disease, and those who currently smoked. Vulnerable populations, such as people with low socioeconomic status, are often found to have relatively poor health and to need support regarding their willingness to be vaccinated. ¹⁶ In addition, a previous study on influenza vaccination suggests that single people are less willing to be vaccinated compared with their married counterparts because single people are not at risk of transmission from coresident family members. 11 Our finding regarding the presence of underlying disease may be related to the fear of COVID-19 transmission because underlying disease a known risk factor for clinical severity of COVID-19 infection.²⁴ Only our finding on tobacco use was inconsistent with previous studies, which have found that smokers often tend to refuse vaccines regardless of the risk of clinical worsening associated with smoking. 10, 11, 33 Further studies should focus on confirming the relationship between smoking and COVID-19 vaccination intention. Overall, we found that 37.5% of the working-age population in Japan was willing to get the COVID-19 vaccine. This percentage is not high enough to achieve herd immunity through the vaccination program.⁵ This acceptance rate is lower than that in other countries, such as China (91.3%), France (58.9%), the US (56.9%), and Russia

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

(54.9%). Furthermore, the acceptance rate is lower than the rate reported in a previous study in Japan (65.7%) that was conducted in September 2020. 19 One possible reason for the low vaccination intention in the current study may be tied to the research period.¹⁵ Our study was conducted in December 2020, right after the start of the COVID-19 vaccination program in the UK and the US, and the media coverage of adverse effects was exaggerated. 34, 35 Another reason is that people of working age have been found to be less willing to get the COVID-19 vaccine compared with older adults, 19 which would affect the present results. These findings have important implications for vaccination intentions, although vaccination acceptance may change after the vaccine is available for administration among the working-age population. The main strengths of this study are the large sample size and the use of a sample from throughout Japan. A limitation of this study is that we recruited study participants from an Internet research company's list of panelists. A previous study on the anti-vaccine movement reported that anti-vaccine messages were more prevalent on the Internet than in other sources.³⁶ Therefore, the participants in the current study may have been particularly likely to access anti-vaccine websites, and this should be taken into account when interpreting the results of our study. Additionally, we conducted the current study before the administration of the COVID-19 vaccination program in Japan; therefore, we could not provide participants with detailed information, such as the vaccination schedule, which may have affected their willingness to get the vaccine. In conclusion, the current study revealed a gender gap in the associations of age and education level with willingness to get the COVID-19 vaccine. In particular, women

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

aged 30–49 years and those with a higher level of education were less willing to get the vaccine. These findings may imply the need for intervention for this population regarding COVID-19 vaccination. Providing education about COVID-19 and influenza vaccination in the workplace may be an effective strategy to increase COVID-19 vaccine uptake. Acknowledgments We thank the current members of the CORoNaWork Project (listed in alphabetical order): Professor Yoshihisa Fujino (present chairperson of the study group), Dr. Hajime Ando, Professor Hisashi Eguchi, Dr. Kazunori Ikegami, Dr. Tomohiro Ishimaru, Dr. Arisa Harada, Dr. Ayako Hino, Dr. Kyoko Kitagawa, Dr. Kosuke Mafune, Professor Shinya Matsuda, Dr. Ryutaro Matsugaki, Professor Koji Mori, Dr. Keiji Muramatsu, Dr. Masako Nagata, Dr. Tomohisa Nagata, Ms. Ning Liu, Professor Akira Ogami, Dr. Rie Tanaka, Dr. Seiishiro Tateishi, Dr. Kei Tokutsu and Professor Mayumi Tsuji. All members are affiliated with the University of Occupational and Environmental Health, Japan. **Funding details** This study was supported and partly funded by the University of Occupational and Environmental Health, Japan; General Incorporated Foundation (Anshin Zaidan); The Development of Educational Materials on Mental Health Measures for Managers at Small-sized Enterprises; Health, Labour and Welfare Sciences Research Grants: Comprehensive Research for Women's Healthcare (H30-josei-ippan-002) and Research for the Establishment of an Occupational Health System in Times of Disaster (H30-

- 306 roudou-ippan-007); scholarship donations from Chugai Pharmaceutical Co., Ltd.; the
- 307 Collabo-Health Study Group; and Hitachi Systems, Ltd.

Disclosure statement

310 The authors declare no conflict of interest.

312 References

308

309

- 313 1. Mahase E. Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95%
- after second dose, paper shows. Bmj 2020; 371:m4826. doi:10.1136/bmj.m4826.
- 315 2. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at
- 316 Pandemic Speed. N Engl J Med 2020; 382:1969-73. doi:10.1056/NEJMp2005630.
- 317 3. Prime Minister of Japan and His Cabinet. Novel Coronavirus Vaccines. Tokyo:
- 318 2021 Feb 17 [accessed 2021 Apr 1].
- 319 https://japan.kantei.go.jp/ongoingtopics/vaccine.html#vaccine05.
- 320 4. Furuse Y, Sando E, Tsuchiya N, Miyahara R, Yasuda I, Ko YK, Saito M,
- 321 Morimoto K, Imamura T, Shobugawa Y, et al. Clusters of Coronavirus Disease in
- 322 Communities, Japan, January-April 2020. Emerg Infect Dis 2020; 26:2176-9.
- 323 doi:10.3201/eid2609.202272.
- 324 5. Bartsch SM, O'Shea KJ, Ferguson MC, Bottazzi ME, Wedlock PT, Strych U,
- 325 McKinnell JA, Siegmund SS, Cox SN, Hotez PJ, et al. Vaccine Efficacy Needed for a
- 326 COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole
- 327 Intervention. Am J Prev Med 2020; 59:493-503. doi:10.1016/j.amepre.2020.06.011.
- 328 6. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic
- 329 Review of Vaccine Acceptance Rates. Vaccines (Basel) 2021; 9.
- 330 doi:10.3390/vaccines9020160.
- 331 7. de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping
- global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-
- 333 scale retrospective temporal modelling study. Lancet 2020; 396:898-908.
- 334 doi:10.1016/s0140-6736(20)31558-0.
- 8. Kuwabara N, Ching MS. A review of factors affecting vaccine preventable
- disease in Japan. Hawai'i journal of medicine & public health: a journal of Asia Pacific
- 337 Medicine & Public Health 2014; 73:376-81.
- 338 9. Hori A, Yoshii S, Isaka Y, Wada K. Factors associated with participation in an
- ongoing national catch-up campaign against rubella: a cross-sectional internet survey
- 340 among 1680 adult men in Japan. BMC Public Health 2021; 21:292.
- 341 doi:10.1186/s12889-021-10340-8.
- 342 10. Wada K, Smith DR. Mistrust surrounding vaccination recommendations by the
- Japanese government: results from a national survey of working-age individuals. BMC
- 344 Public Health 2015; 15:426. doi:10.1186/s12889-015-1772-8.

- 345 11. Wada K, Smith DR. Influenza vaccination uptake among the working age
- population of Japan: results from a national cross-sectional survey. PLoS One 2013;
- 347 8:e59272. doi:10.1371/journal.pone.0059272.
- 348 12. Bonanni P, Zanella B, Santomauro F, Lorini C, Bechini A, Boccalini S. Safety
- and perception: What are the greatest enemies of HPV vaccination programmes?
- 350 Vaccine 2018; 36:5424-9. doi:10.1016/j.vaccine.2017.05.071.
- 351 13. Suzuki Y, Sukegawa A, Nishikawa A, Kubota K, Motoki Y, Asai-Sato M, Ueda
- 352 Y, Sekine M, Enomoto T, Hirahara F, et al. Current knowledge of and attitudes toward
- 353 human papillomavirus-related disease prevention among Japanese: A large-scale
- questionnaire study. The journal of obstetrics and gynaecology research 2019; 45:994-
- 355 1005. doi:10.1111/jog.13929.
- 356 14. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19
- 357 vaccine acceptance in the US. EClinicalMedicine 2020; 26:100495.
- 358 doi:10.1016/j.eclinm.2020.100495.
- 359 15. Wang K, Wong EL, Ho KF, Cheung AW, Yau PS, Dong D, Wong SY, Yeoh
- 360 EK. Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine
- 361 Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong,
- 362 China: Repeated Cross-Sectional Surveys. Vaccines (Basel) 2021; 9.
- 363 doi:10.3390/vaccines9010062.
- 364 16. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among
- adults in the United States: How many people would get vaccinated? Vaccine 2020;
- 366 38:6500-7. doi:10.1016/j.vaccine.2020.08.043.
- 367 17. Chen M, Li Y, Chen J, Wen Z, Feng F, Zou H, Fu C, Chen L, Shu Y, Sun C. An
- online survey of the attitude and willingness of Chinese adults to receive COVID-19
- 369 vaccination. Hum Vaccin Immunother 2021:1-10.
- 370 doi:10.1080/21645515.2020.1853449.
- 371 18. Dodd RH, Cvejic E, Bonner C, Pickles K, McCaffery KJ. Willingness to
- 372 vaccinate against COVID-19 in Australia. The Lancet Infectious diseases 2020.
- 373 doi:10.1016/s1473-3099(20)30559-4.
- 374 19. Yoda T, Katsuyama H. Willingness to Receive COVID-19 Vaccination in Japan.
- 375 Vaccines (Basel) 2021; 9. doi:10.3390/vaccines9010048.
- 376 20. Fujino Y, Ishimaru T, Eguchi H, Tsuji M, Tateishi S, Ogami A, Mori K,
- 377 Matsuda S. Protocol for a nationwide Internet-based health survey in workers during the
- 378 COVID-19 pandemic in 2020. JUOEH 2021:in press.
- 379 doi:10.1101/2021.02.02.21249309.
- 380 21. Looi MK. Covid-19: Japan declares second state of emergency as Asia struggles
- 381 with virus surge. Bmj 2021; 372:n141. doi:10.1136/bmj.n141.
- 382 22. Baraniuk C. Covid-19: How the UK vaccine rollout delivered success, so far.
- 383 Bmj 2021; 372:n421. doi:10.1136/bmj.n421.
- 384 23. Organisation for Economic Co-operation and Development. Exchange rates.
- Palis: 2021 [accessed 2021 Apr 1]. https://data.oecd.org/conversion/exchange-
- 386 rates.htm?fbclid=IwAR2Bn6JlF8WfAbVhwDEiKFhG0_rsTu-
- 387 iLq1PW47o1ujebwc7CWF0e0wUx_A.
- 388 24. Alley SJ, Stanton R, Browne M, To QG, Khalesi S, Williams SL, Thwaite TL,
- 389 Fenning AS, Vandelanotte C. As the Pandemic Progresses, How Does Willingness to
- 390 Vaccinate against COVID-19 Evolve? Int J Environ Res Public Health 2021; 18.
- 391 doi:10.3390/ijerph18020797.
- 392 25. Neumann-Böhme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J,
- 393 Schreyögg J, Stargardt T. Once we have it, will we use it? A European survey on

- willingness to be vaccinated against COVID-19. Eur J Health Econ 2020; 21:977-82.
- 395 doi:10.1007/s10198-020-01208-6.
- 396 26. Unroe KT, Evans R, Weaver L, Rusyniak D, Blackburn J. Willingness of Long-
- 397 Term Care Staff to Receive a COVID-19 Vaccine: A Single State Survey. J Am Geriatr
- 398 Soc 2020. doi:10.1111/jgs.17022.
- 399 27. Graffigna G, Palamenghi L, Boccia S, Barello S. Relationship between Citizens'
- 400 Health Engagement and Intention to Take the COVID-19 Vaccine in Italy: A Mediation
- 401 Analysis. Vaccines (Basel) 2020; 8. doi:10.3390/vaccines8040576.
- 402 28. Tsuda K, Yamamoto K, Leppold C, Tanimoto T, Kusumi E, Komatsu T, Kami
- 403 M. Trends of Media Coverage on Human Papillomavirus Vaccination in Japanese
- 404 Newspapers. Clin Infect Dis 2016; 63:1634-8. doi:10.1093/cid/ciw647.
- 405 29. Sakamoto A, Chanyasanha C, Sujirarat D, Matsumoto N, Nakazato M. Factors
- 406 associated with pneumococcal vaccination in elderly people: a cross-sectional study
- among elderly club members in Miyakonojo City, Japan. BMC Public Health 2018;
- 408 18:1172. doi:10.1186/s12889-018-6080-7.
- 409 30. Yi S, Nonaka D, Nomoto M, Kobayashi J, Mizoue T. Predictors of the uptake of
- 410 A (H1N1) influenza vaccine: findings from a population-based longitudinal study in
- 411 Tokyo. PLoS One 2011; 6:e18893. doi:10.1371/journal.pone.0018893.
- 412 31. Nguyen T, Henningsen KH, Brehaut JC, Hoe E, Wilson K. Acceptance of a
- 413 pandemic influenza vaccine: a systematic review of surveys of the general public.
- 414 Infection and drug resistance 2011; 4:197-207. doi:10.2147/idr.s23174.
- 415 32. Iwasa T, Wada K. Reasons for and against receiving influenza vaccination in a
- 416 working age population in Japan: a national cross-sectional study. BMC Public Health
- 417 2013; 13:647. doi:10.1186/1471-2458-13-647.

- 418 33. Matsui D, Shigeta M, Ozasa K, Kuriyama N, Watanabe I, Watanabe Y. Factors
- 419 associated with influenza vaccination status of residents of a rural community in Japan.
- 420 BMC Public Health 2011; 11:149. doi:10.1186/1471-2458-11-149.
- 421 34. Klimek L, Novak N, Hamelmann E, Werfel T, Wagenmann M, Taube C, Bauer
- 422 A, Merk H, Rabe U, Jung K, et al. Severe allergic reactions after COVID-19
- 423 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position
- 424 statement of the German Allergy Societies: Medical Association of German
- 425 Allergologists (AeDA), German Society for Allergology and Clinical Immunology
- 426 (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA).
- 427 Allergo journal international 2021; 30:51-5. doi:10.1007/s40629-020-00160-4.
- 428 35. Loomba S, de Figueiredo A, Piatek SJ, de Graaf K, Larson HJ. Measuring the
- 429 impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA.
- 430 Nature human behaviour 2021; 5:337-48. doi:10.1038/s41562-021-01056-1.
- 431 36. Davies P, Chapman S, Leask J. Antivaccination activists on the world wide web.
- 432 Archives of disease in childhood 2002; 87:22-5. doi:10.1136/adc.87.1.22.

Table 1. Characteristics of the study population.

435

437

	n (%)
Gender	
Men	13,814 (51.1)
Women	13,222 (48.9)
Age (years)	
20–29	1,905 (7.0)
30–39	4,858 (18.0)
40–49	8,011 (29.6)
50–59	9,012 (33.3)
60–65	3,250 (12.0)
Education level	
Junior high or high school	7,321 (27.1)
Vocational school or college	6,544 (24.2)
University or graduate school	13,171 (48.7)
Marital status	, , ,
Single	9,164 (33.9)
Divorced or widowed	2,843 (10.5)
Married	15,029 (55.6)
Annual household income (JPY)	, , ,
< 2,000,000	1,709 (6.3)
2,000,000-3,999,999	5,548 (20.5)
4,000,000-7,999,999	11,927 (44.1)
≥ 8,000,000	7,852 (29.1)
Underlying disease	, , ,
No	17,526 (64.8)
Yes	9,510 (35.2)
Smoking status	- , (,
Never smoked	14,587 (54.0)
Former smoker	5,445 (20.1)
Current smoker	7,004 (25.9)
Received the influenza vaccine during the current season	.,,
No	15,411 (57.0)
Yes	11,625 (43.0)
Fear of COVID-19 transmission	, (,
No	7,019 (26.0)
Yes	20,017 (74.0)
Willing to get the COVID-19 vaccine	-0,017 (7.110)
No	16,889 (62.5)
Yes	10,147 (37.5)

436 JPY: Japanese yen; COVID-19: coronavirus disease 2019

Table 2. Characteristics of the study population by willingness to get the COVID-19

vaccine and gender.

438

	M	len	Women		
	Willing	Unwilling	Willing	Unwilling	
	n = 5,780	n = 8,034	n = 4,367	n = 8,855	
	(41.8%)	(58.2%)	(33.0%)	(67.0%)	
	n (%)	n (%)	n (%)	n (%)	
Age (years)					
20–29	66 (34.4)	126 (65.6)	604 (35.3)	1,109 (64.7)	
30–39	424 (37.8)	698 (62.2)	1,192 (31.9)	2,544 (68.1)	
40–49	1,487 (39.1)	2,316 (60.9)	1,282 (30.5)	2,926 (69.5)	
50-59	2,540 (41.9)	3,527 (58.1)	1,034 (35.1)	1,911 (64.9)	
60–65	1,263 (48.0)	1,367 (52.0)	255 (41.1)	365 (58.9)	
Education level		, , ,	,	, ,	
Junior high or high school	1,562 (40.1)	2,335 (59.9)	1,212 (35.4)	2,212 (64.6)	
Vocational school or college	818 (40.7)	1,194 (59.3)	1,523 (33.6)	3,009 (66.4)	
University or graduate school	3,400 (43.0)	4,505 (57.0)	1,632 (31.0)	3,634 (69.0)	
Marital status		, , ,			
Single	1,195 (35.3)	2,189 (64.7)	1,724 (29.8)	4,056 (70.2)	
Divorced or widowed	391 (39.9)	590 (60.1)	663 (35.6)	1,199 (64.4)	
Married	4,194 (44.4)	5,255 (55.6)	1,980 (35.5)	3,600 (64.5)	
Annual household income (JPY)					
< 2,000,000	219 (31.1)	486 (68.9)	289 (28.8)	715 (71.2)	
2,000,000-3,999,999	897 (38.8)	1,414 (61.2)	1,056 (32.6)	2,181 (67.4)	
4,000,000-7,999,999	2,585 (41.2)	3,694 (58.8)	1,866 (33.0)	3,782 (67.0)	
\geq 8,000,000	2,079 (46.0)	2,440 (54.0)	1,156 (34.7)	2,177 (65.3)	
Underlying disease					
No	3,201 (38.0)	5,221 (62.0)	2,844 (31.2)	6,260 (68.8)	
Yes	2,579 (47.8)	2,813 (52.2)	1,523 (37.0)	2,595 (63.0)	
Smoking status					
Never smoked	1,999 (38.4)	3,213 (61.6)	2,976 (31.7)	6,399 (68.3)	
Former smoker	1,664 (44.4)	2,083 (55.6)	554 (32.6)	1,144 (67.4)	
Current smoker	2,117 (43.6)	2,738 (56.4)	837 (38.9)	1,312 (61.1)	
Received the influenza vaccine during the	he current season				
No	2,570 (30.6)	5,825 (69.4)	1,656 (23.6)	5,360 (76.4)	
Yes	3,210 (59.2)	2,209 (40.8)	2,711 (43.7)	3,495 (56.3)	
Fear of COVID-19 transmission					
No	986 (23.9)	3,146 (76.1)	542 (18.8)	2,345 (81.2)	
Yes	4,794 (49.5)	4,888 (50.5)	3,825 (37.0)	6,510 (63.0)	

440 COVID-19: coronavirus disease 2019; JPY: Japanese yen

Table 3. Factors associated with willingness to get the COVID-19 vaccine by gender.

	Men			Women		
	aOR ^a	(95% CI)	P-value	aOR ^a	(95% CI)	P-value
Age (years)						
20–29	1.00	-	-	1.00	-	-
30–39	1.16	(0.84-1.60)	.366	0.86	(0.76-0.97)	.015
40–49	1.23	(0.90-1.66)	.191	0.80	(0.71-0.91)	< .001
50–59	1.38	(1.02-1.86)	.039	0.99	(0.88-1.13)	.918
60–65	1.76	(1.30-2.40)	< .001	1.28	(1.06-1.55)	.010
Education level						
Junior high or high school	1.00	-	-	1.00	-	-
Vocational school or college	1.04	(0.93-1.16)	.461	0.93	(0.84-1.02)	.099
University or graduate school	1.13	(1.04-1.22)	.003	0.83	(0.75-0.91)	< .001
Marital status						
Single	1.00	-	-	1.00	-	-
Divorced or widowed	1.13	(0.97-1.31)	< .001	1.30	(1.16-1.46)	< .001
Married	1.37	(1.26-1.49)	< .001	1.30	(1.20-1.40)	< .001
Annual household income (JPY)						
< 2,000,000	1.00	-	-	1.00	-	-
2,000,000-3,999,999	1.45	(1.21-1.73)	< .001	1.20	(1.03-1.41)	.020
4,000,000-7,999,999	1.61	(1.36-1.90)	< .001	1.23	(1.06-1.42)	.007
\geq 8,000,000	1.91	(1.61-2.26)	< .001	1.32	(1.13-1.53)	< .001
Underlying disease						
No	1.00	-	-	1.00	-	-
Yes	1.43	(1.34-1.54)	< .001	1.29	(1.19-1.39)	< .001
Smoking status						
Never smoked	1.00	-	-	1.00	-	-
Former smoker	1.21	(1.11-1.33)	< .001	1.04	(0.93-1.16)	.521
Current smoker	1.20	(1.11-1.30)	< .001	1.36	(1.24-1.51)	< .001
Received the influenza vaccine during	the curre	ent season				
No	1.00	-	_	1.00	-	-
Yes	3.28	(3.05-3.52)	< .001	2.53	(2.35-2.73)	< .001
Fear of COVID-19 transmission						
No	1.00	-	-	1.00	-	-
Yes	3.09	(2.85 - 3.35)	< .001	2.54	(2.29-2.81)	< .001

⁴⁴³ COVID-19: coronavirus disease 2019; aOR: adjusted odds ratio; CI: confidence

⁴⁴⁴ interval; JPY: Japanese yen

^{445 &}lt;sup>a</sup>Adjusted for age